Bayer AG (BAYRY) Given Consensus Rating of “Buy” by Brokerages
Bayer AG (NASDAQ:BAYRY) has received an average rating of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $148.00.
Several equities research analysts have recently weighed in on BAYRY shares. BNP Paribas raised shares of Bayer AG from a “neutral” rating to an “outperform” rating in a report on Monday, September 25th. Zacks Investment Research raised shares of Bayer AG from a “hold” rating to a “buy” rating and set a $148.00 target price on the stock in a report on Tuesday, September 19th. ValuEngine lowered shares of Bayer AG from a “buy” rating to a “hold” rating in a report on Friday, September 22nd. Finally, Berenberg Bank lowered shares of Bayer AG from a “buy” rating to a “hold” rating in a report on Monday, July 3rd.
Bayer AG (NASDAQ:BAYRY) opened at 34.80 on Friday. Bayer AG has a 52-week low of $22.88 and a 52-week high of $35.41. The company has a market capitalization of $121.40 billion and a P/E ratio of 20.04. The stock has a 50 day moving average of $33.72 and a 200-day moving average of $32.26.
Bayer AG (NASDAQ:BAYRY) last announced its quarterly earnings results on Thursday, July 27th. The company reported $1.99 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.12. The firm had revenue of $13.41 billion for the quarter, compared to analyst estimates of $14.45 billion. Bayer AG had a net margin of 10.90% and a return on equity of 13.03%. On average, equities analysts forecast that Bayer AG will post $2.22 earnings per share for the current year.
About Bayer AG
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.